Diagnostic of global coagulation parameters is part of the daily clinical routine practice in
conservative as well in operative disciplines. The correct interpretation of in vitro test results …

The introduction of several oral direct anticoagulants within the past 2–3 years has
dramatically changed clinical practice and has also impacted on utilization and …

Direct oral anticoagulants (DOACs) have been established and already registered for
clinical use on a wide basis in the United States and Europe. Different from the vitamin K …

Because their anticoagulant effect is dose predictable, steady, and little influenced by diet
and drugs, laboratory monitoring was deemed unnecessary in trials on venous and arterial …

Sažetak The tests currently employed within most haemostasis laboratories to monitor
anticoagulant therapy largely comprise the prothrombin time (PT)/International Normalised …

At variance with vitamin K antagonists, the new oral anticoagulants (NOAs) can be
prescribed at fixed dosage without adjustment by laboratory testing. However, this does not …

Although no laboratory monitoring is needed for new anticoagulants, the measurement of
their actvity is required in special clinical situations. Standardised tests have been …

Direct oral anticoagulants (DOAC s), including the direct thrombin inhibitor, dabigatran, and
the direct factor Xa (FX a) inhibitors, rivaroxaban, apixaban and edoxaban, are approved for …

Purpose Available evidence on laboratory monitoring of coagulation assays and reversal
strategies for the management of hemorrhagic events associated with the newer …

BACKGROUND The new oral anticoagulants (NOAs) dabigatran, rivaroxaban, and
apixaban have proved effective and safe when used in clinical trials, without a need to …